Rosiglitazone vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.1 | 0.0396 | 0.231 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.15 | 0.0706 | 0.291 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.05 | -0.203 | 0.103 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.667 | 0.203 | 2.18 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.63 | 0.163 | 2.43 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with a serious adverse event on Rosiglitazone than on Placebo | 20 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Rosiglitazone | Eligible participants received unit oral rosiglitazone extended release (RSG XR) 4 mg for one month with or without food. Participants received escalated dose of rosiglitazone-XR for next 12 months and were followed-up to 30 days. | 4 | 40 | EG001 | ClinicalTrials.gov |
| Group 2 | Placebo | Eligible participants received unit oral dose of visually matching Placebo 4 mg for one month. Participants received escalated dose of 8 mg matching placebo for next 12 months and were followed-up to 30 days. | 6 | 40 | EG000 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, serious adverse events | ClinicalTrials.gov |
| Time frame | Up to 13 months | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease | ClinicalTrials.gov |
| NCT number | NCT00265148 | ClinicalTrials.gov |
| Phases | PHASE2 | ClinicalTrials.gov |
| Conditions | Alzheimer's Disease | ClinicalTrials.gov |
| Interventions | Rosiglitazone, Placebo | ClinicalTrials.gov |
| Lead sponsor | GlaxoSmithKline | ClinicalTrials.gov |
| Results first posted | 2020-11-18 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00265148?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.